Merck (MRK) Rallies on Nov. 11, 2025: FDA Approves New Keytruda Companion Diagnostic; Fresh SITC Combo Data, and Dow Momentum
Published: November 11, 2025 At a glance (today) Market move: MRK helps lead the Dow’s advance By early afternoon Tuesday, Merck & Co. (NYSE: MRK) shares were up about 3.9%, helping lead the Dow Jones Industrial Average higher; Nike and Merck together contributed an estimated ~36 points to the index’s ~386‑point climb at that time. MarketWatch In a separate Data Talk update, MRK was up for a sixth straight session, putting it on pace for its longest winning streak since August and tracking toward its highest close since Oct. 1—contingent on late‑day trading. Morningstar Regulatory update: FDA okays Promega’s OncoMate®